Introduction: Respiratory Syncytial Virus (RSV) infection causes seasonal respiratory illness in both children and adults, with increasing recognition of its impact in older adults with chronic comorbidities. This study aimed to characterize adult patients hospitalized with RSV infection in Switzerland and identify comorbidities linked to poor outcomes. Methods: Adults hospitalized with RSV infection between May 2022 and April 2024 at a Swiss public teaching hospital were included in this retrospective observational study. To assess the association between comorbidities and patient outcomes, separate multivariable regression analyses for each comorbidity, adjusted for age and sex, were performed. The primary composite endpoint was ’severe course’ (in-hospital death or intensive care unit (ICU) admission), secondary endpoints included in-hospital death, ICU admission, and length of stay. Results: Among 136 included patients (mean age 78, 38% male), 98% had comorbidities, most commonly cardiovascular (75.7%), respiratory (51%), and chronic kidney disease (CKD) (36.7%). Further, 18.4% experienced a severe course. The ICU admission rate was 14.0%, in-hospital mortality 6.6%, and the median hospital stay of survivors was 6 days (IQR 4–10). CKD was significantly associated with severe course (OR 2.64, p = 0.045) and in-hospital mortality (OR 11.6, p = 0.025), while immunosuppression predicted ICU admission (OR 5.7, p = 0.018). Length of stay was not linked to any comorbidities. Conclusions: In this cohort of hospitalized adults, mainly elderly individuals with chronic comorbidities were tested positive for RSV. CKD and immunosuppression were associated with severe course. Prevention strategies, including RSV vaccination, should prioritize these high-risk populations.

Respiratory syncytial virus (RSV) is a major cause of respiratory illness, particularly in children, yet its burden in adults—especially in older adults—remains under-recognized. We analyzed RSV-related hospitalizations in Switzerland from 2017 to 2023 using national data from the Federal Statistical Office, including cases with RSV coded as either a primary or secondary diagnosis. Over 35,000 RSV-related hospitalizations were recorded. The highest incidence occurred in children under 10 years (390 per 100,000/year), with a second peak in adults ≥ 80 years (151 per 100,000/year). Older adults (≥60 years) accounted for more than 9700 hospitalizations overall, with an average of over 16,600 total hospital days per year. Average length of stay (LOS) was shortest in young children (4.6 days) and highest in adolescents (13.9 days), while in adults, it increased from 6.8 days (age 20–29) to 12.3 (age ≥ 80). Mechanical ventilation rates peaked at 12.6% in 60–69 year olds, and in-hospital mortality at 7.1% in those ≥80 years. In adults, RSV was more often recorded as a secondary diagnosis and commonly associated with chronic comorbidities, including chronic obstructive pulmonary disease, heart failure, kidney disease, and diabetes. Frailty-related diagnoses—such as cognitive or motor impairment, delirium, and need for nursing care—were also frequent. These findings highlight the importance of improved adult RSV surveillance and targeted prevention strategies in high-risk populations.

Respiratory syncytial virus (RSV) is a major cause of respiratory illness, particularly in children, yet its burden in adults – especially in older adults – remains under-recognized. We analyzed RSV-related hospitalizations in Switzerland from 2017 to 2023 using national data from the Federal Statistical Office, including cases with RSV coded as either a primary or secondary diagnosis. Over 35,000 RSV-related hospitalizations were recorded. The highest incidence occurred in children under 10 years (390 per 100,000/year), with a second peak in adults ≥80 years (151 per 100,000/year). Older adults (≥60 years) accounted for more than 9,700 hospitalizations overall, with an average of over 16,600 total hospital days per year. Average length of stay (LOS) was shortest in young children (4.6 days) and highest in adolescents (13.9 days), while in adults it increased from 6.8 days (age 20-29) to 12.3 (age ≥80). Mechanical ventilation rates peaked at 12.6% in 60-69 year olds, and in-hospital mortality at 7.1% in those ≥80 years. In adults, RSV was more often recorded as a secondary diagnosis and commonly associated with chronic comorbidities, including chronic obstructive pulmonary disease, heart failure, kidney disease, and diabetes. Frailty-related diagnoses – such as cognitive or motor impairment, delirium, and need for nursing care – were also frequent. These findings highlight the importance of improved adult RSV surveillance and targeted prevention strategies in high-risk populations.